Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results

n and our financial performance.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to successfully commercialize Cinryze;
  • our ability to receive regulatory approval for the use of Cinryze for the acute treatment of HAE;
  • the availability of third party payer reimbursement for Cinryze patients;
  • our ability to develop a clinical development program for maribavir;
  • approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze;
  • fluctuations in wholesaler order patterns and inventory levels;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for the product;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin and Cinryze;
  • the timing of regulatory submissions and approvals;
  • actions by the FDA, EMEA and the Internal Revenue Service or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • an impairment of our intangible assets if our market capitalization remains less than our book value;
  • the timing and results of anticipated events in our clinical development programs; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring produ

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
(Date:7/31/2014)... 2014 Sales Horizons, a leader in ... sales training course – Mastering the Complex Sale ... , Drawn from proven sales training programs used by ... Complex Sale online sales training course is available to ... face-to-face contact with customers, like technical support, engineers, clinical ...
(Date:7/30/2014)...  Decision Resources Group finds that the majority ... the United States believe that ... be the level of savings achievable by their ... cost to patients. Payers plan to leverage preferential ... expectations in order to encourage physician prescribing of ...
(Date:7/30/2014)... 30, 2014 While administrative claims ... services research for a relatively long period of ... regarding the use of these ‘big data’ for ... By combining today’s powerful computer technology with the ... ‘big data’ holds significant promise for identifying optimal ...
(Date:7/30/2014)... NewYork (PRWEB) July 30, 2014 ... the increase of personal health expenditure as well ... health care system, China diagnostic reagent industry has ... occupy over 90%. In 2013, Chinese in vitro ... RMB16.61 billion came from in vitro diagnostic reagents. ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3
... SANFORD, Maine, Jan. 31, 2012  Maine Manufacturing, LLC announced ... GE Healthcare granting Maine Manufacturing the exclusive right to ... line.  Maine Manufacturing, which has been manufacturing the FAST ... FAST Slides and accessories including FAST Quant, direct to ...
... Jan. 26, 2012 Life Technologies Corporation (NASDAQ: ... company,s presentations at the following upcoming investment conferences in ... Life Technologies will present at the Leerink Swann 2012 ... a.m. ET. Life Technologies will also present ...
... 2012  ZyGEM Corp. Ltd., a developer and marketer of ... nucleic acids, today announced that it has signed an ... DNA and RNA extraction kits.  SDL was established by ... as part of the Saudi Arabian government,s drive to ...
Cached Biology Technology:Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products 2Life Technologies to Present at Upcoming Investment Conferences in February 2ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd. 2ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd. 3
(Date:7/30/2014)... (ACS) announced today that David L. Kaplan, Ph.D., will ... & Engineering as editor-in-chief. With the first issue ... will feature high-quality research in the rapidly burgeoning field ... materials that interact with living or biological systems. , ... tremendous growth in the field of biomaterials over the ...
(Date:7/30/2014)... San Antonio Life Sciences Institute (SALSI), a joint venture ... and The University of Texas Health Science Center at ... Initiative Pilot Program. The winners, Emily Boice from UTSA ... receive $25,000 for their project titled, "Novel engineered ferritins ... environment." , Boice and Huang,s research is focused on ...
(Date:7/30/2014)... infection could be as simple as inserting a medicated, ... of Washington bioengineers have discovered a potentially faster way ... contracting HIV. Their method spins the drug into silk-like ... releasing higher doses of the drug than possible with ... "This could offer women a potentially more effective, discreet ...
Breaking Biology News(10 mins):ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... a moth gene has been shown to be able to produce ... study led by researchers from Lund University in Sweden. In the ... tailored production of pheromones for pest control. Male moths can ... of several hundred metres. The females produce sexual pheromones scent ...
... International Osteoporosis Foundation (IOF) and ESCEO have announced that ... to the European Congress on Osteoporosis & Osteoarthritis (ESCEO13-IOF) ... indicate a record number of delegates, making the ESCEO13-IOF ... research in the field, as well the world,s largest ...
... the name suggests, you can,t digest resistant starch so it ... form it entered your mouth. As unlovely as that seems, ... things, including decreasing bowel pH and transit time, and increasing ... growth of good bugs while keeping bad bugs at bay. ...
Cached Biology News:Towards a new moth perfume 2Study shows that diet of resistant starch helps the body resist colorectal cancer 2
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
... used to test the crossreactivity of an ... are commonly used as blocking reagents or ... 19 different protein preparations on a nitrocellulose ... species specificity, QC of purified antibodies, selection ...
... new HydroFlex platform provides excellent performance, ... of 96-well format applications, including washing ... arrays, and vacuum filtration-to-waste, such as ... on-line control features set new standards ...
... Clean and Accurate Results Laser Capture ... the sensitivity and accuracy of molecular assays ... types and multi-cellular structures isolated from whole ... to microdissection-developed in 1996 at the National ...
Biology Products: